T1	Participants 13 78	rheumatoid arthritis patients treated with etanercept monotherapy
T2	Participants 343 401	etanercept-treated patients with rheumatoid arthritis (RA)
T3	Participants 966 1035	Patients from TEMPO and RADIUS II who received etanercept monotherapy
T4	Participants 730 795	patients initiating etanercept (monotherapy or with methotrexate)
T5	Participants 1399 1439	patients with lower baseline CDAI scores
